DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Spectroscopic Imaging at 4T: A Drug Challenge Study

Information source: Mclean Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: AOD Effects and Consequences

Intervention: Alprazolam (Drug); Dextroamphetamine (Drug)

Phase: N/A

Status: Completed

Sponsored by: Mclean Hospital

Official(s) and/or principal investigator(s):
John E Jensen, Ph.D., Principal Investigator, Affiliation: Mclean Hospital

Summary

An advanced technique for rapid magnetic resonance proton spectroscopic imaging (1H-MRSI) will be employed in a drug challenge study in healthy volunteers to spatially map and measure acute changes in the brain chemicals GABA, glutamate and glutamine after administration of a drug. Three condition will be tested in a double-blind fashion, i)depressant, ii)stimulant, iii)placebo. It is hypothesized that unique and reproducible spatial and directional metabolic response patterns will be observed, unique to each condition within the brain.

Clinical Details

Official title: Spectroscopic Imaging of GABA and Glutamate/Glutamine in Healthy Volunteers at 4T: A Double Blind, Crossover Drug Challenge Study

Study design: Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Primary outcome: Magnitude of metabolite level changes throughout the brain with separate administration of Dexedrine and Alprazolam

Secondary outcome: Spatial distribution of metabolite level changes throughout the brain with separate administration of Dexedrine and Alprazolam

Detailed description: Proton magnetic resonance spectroscopy (1H MRS) is a powerful tool for assessing neurochemistry non-invasively in vivo. However, the primary shortcoming in most studies is the lack of spatial coverage afforded by the typical single-voxel design. Limits on participant tolerance and financial resources restrict single-voxel studies to an examination of one or two carefully chosen voxels per scan, thus inadequately addressing the question of focal vs. global pathophysiology. A secondary shortcoming is that most studies report on either GABA or glutamate-glutamine (Glu-Gln) due to the technically demanding spectral-editing techniques that must be implemented in order to resolve and quantify those metabolites with any accuracy. 1H MRS imaging (MRSI) can partially overcome these limitations by providing a global picture of brain chemistry rather than just the focal snapshot afforded by the single-voxel design. However, the scan time necessary for collecting enough data for adequate spatial resolution and signal-to-noise, particularly if also using specialized spectral-editing techniques, is still too lengthy. We recently developed a method that combines Spectroscopic Imaging with the MEGAPRESS-based difference-editing acquisition for optimal GABA detection as well as for optimal detection of Glu and Gln. This MEGACSI sequence will permit us to obtain the maximum amount of neurochemical information in a clinically sound scan time, while using the current state-of-the-art MRS editing methods for optimal detection of GABA, Glu, and Gln.

Eligibility

Minimum age: 21 Years. Maximum age: 45 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Participants will be male volunteers between the ages of 21-45

- Non-smoking participants are preferred, but will admit those who smoke less than 5

cigarettes per day

- Participants must be able to read screening materials including consent form and give

informed consent Exclusion Criteria:

- Participants cannot meet DSM-IV criteria for lifetime and/or current mood, anxiety,

psychotic, and alcohol/drug use disorders as identified by the SCID

- Participants cannot be taking any prescription medication (except oral

contraceptives, certain short-term anti-fungal agents, and some topical creams for dermal conditions) or nutritional supplements

- Participants cannot be taking any psychotropic medications

- Participants cannot have a history of major head trauma resulting in cognitive

impairment, seizure, or other neurological disorders.

- Participants cannot have any conditions that are contraindicated for MRI

- Participants cannot have a family history of alcoholism

- Participants cannot have any abnormal blood chemistries/urinalysis results or any

other medical condition that may affect drug disposition (e. g., Hepatitis C)

- Participants cannot have current or past cardiac problems, and they also cannot have

a family history of sudden death or ventricular arrhythmia

- Participants who, in the investigators' judgment, will not likely be able to comply

with the study protocol.

- Participants cannot have any clinically significant findings in the structural

anatomic brain scans (per the MRI report read by a board-certified radiologist).

Locations and Contacts

McLean Imaging Center, McLean Hospital, Belmont, Massachusetts 02478-9106, United States
Additional Information

Starting date: June 2013
Last updated: March 27, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017